Esperion Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Esperion Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on May 28, 2026, featuring key proposals including a 7,000,000 share increase to its 2022 Stock Option and Incentive Plan.
NASDAQ
Esperion Therapeutics, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
Esperion Therapeutics is asking stockholders to approve an amendment to its 2022 Stock Option and Incentive Plan to increase the number of shares available for issuance by 6,250,000.
NASDAQ
DEF 14A: Esperion Therapeutics Seeks Stockholder Approval for Equity Plan Amendments at 2024 Annual Meeting
Esperion Therapeutics is asking stockholders to approve amendments to its stock option and employee stock purchase plans at the upcoming annual meeting to increase the number of shares available for issuance.